BioAtla, Inc. (BCAB) Social Stream



BioAtla, Inc. (BCAB): $1.81

0.06 (+3.43%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add BCAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#301 of 359

in industry

BIOATLA INC (BCAB) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering BIOATLA INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-18 4 $75 $64 $70.5 $1.72 3998.84%
2022-01-02 4 $75 $58 $69 $1.72 3911.63%
2022-01-12 3 $75 $58 $69 $1.72 3911.63%
2022-01-17 3 $75 $58 $67.25 $1.72 3809.88%
2022-02-04 3 $68 $36 $57.5 $1.72 3243.02%
2022-03-01 3 $68 $36 $53.5 $1.72 3010.47%
2022-03-11 3 $68 $31 $46.75 $1.72 2618.02%
2022-05-05 4 $68 $25 $42.4 $1.72 2365.12%
2022-05-06 4 $68 $21 $36.2 $1.72 2004.65%
2022-07-22 4 $68 $21 $37.5 $1.72 2080.23%
2022-08-10 4 $68 $20 $34.2 $1.72 1888.37%
2022-09-15 5 $68 $17 $30.833 $1.72 1692.62%
2022-11-04 5 $36 $17 $23.4 $1.72 1260.47%
2023-01-05 5 $25 $17 $21.4 $1.72 1144.19%
2023-03-24 5 $25 $17 $20.8 $1.72 1109.3%
2023-03-27 6 $25 $12 $18.4 $1.72 969.77%
2023-03-28 6 $25 $12 $17.5 $1.72 917.44%
2023-08-02 6 $25 $12 $16.333 $1.72 849.59%

The Trend in the Analyst Price Target


Over the past 46 weeks, BCAB's average price target has gone down $14.17.

BCAB reports an average of 361.08% for its upside potential over the past 39 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-01-05 6 36 17 23.833 8.25 188.88%
2023-01-05 5 36 17 23.833 8.25 188.88%
2023-03-27 6 25 12 18.400 2.49 638.96%
2023-08-02 6 25 12 16.333 2.98 448.09%
2023-08-02 6 25 12 16.666 2.98 459.26%

BCAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 26 months, BCAB's average broker recommendation rating improved by 0.5.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, BIOATLA INC's upside potential (average analyst target price relative to current price) is higher than 2448.68% of them.
  • BCAB has a greater number of analysts covering the stock than 451.53% of all US stocks.
  • In terms of how BIOATLA INC fares relative to stocks in the mid market cap category, note that its variance in analysts' estimates is lower than -1614.68% of that group.
  • In the context of stocks in the mid market cap category, BIOATLA INC's average analyst price target is greater than 1157.7% of them.

Stocks similar to BIOATLA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are TIL, RXRX, and EXAI.

What is the outlook for BCAB? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!